Hippocampus—Related Cognitive and Affective Impairments in Patients With Breast Cancer—A Systematic Review

Abstract

Background: Although improvements in medical treatment lead to a steadily rising survival rate of breast cancer patients (BCP), it is associated with a decrease in cognitive and affective function. The hippocampus, a brain region with a high influence on both cognitive and affective function, is increasingly becoming the focus of current research because of its high vulnerability to adverse direct (chemotherapeutic agents, endocrine therapeutic agents, and radiation) or indirect (stress and other psycho-social factors) treatment-related effects. Methods: This systematic review analyses current data from literature combining hippocampus-related brain changes due to breast cancer treatment with associated cancer-related cognitive and affective impairments (CRCI/CRAI). The seven studies that met the inclusion criteria consisted of six cross-sectional studies and one longitudinal study. Results: The study results indicate hippocampal differences across all types of treatment. Those differences include volume loss, deformation, and changes in functional connectivity. They are associated with CRCI, revealing executive function as well as working memory, episodic memory, and prospective memory as the most affected domains. Although an interaction between hippocampus-related brain changes, CRCI, and CRAI can be hypothesized, CRAI are less reflected in current research. Discussion: More research including longitudinal assessments with better overall methodology is needed to fully understand the interaction between hippocampal alterations and both CRCI and CRAI due to breast cancer treatment.

Multi-institutional development and external validation of machine learning-based models to predict relapse risk of pancreatic ductal adenocarcinoma after radical resection

“…It turned out that machine learning techniques were superior to conventional regression-based analyses in terms of the predictive performance. In accordance with various studies investigating the prognostic factors of PDAC [ 11 , 31 , 32 ], lymph node status (N-stage), vascular invasion and CA199 are independent predictors for both 1- and 2-year relapse. Although the RF model had the highest AUROC in the training set, the SVM model and KNN model showed better robustness to predict 1- and 2-year relapse in the validation set, respectively.…”

Animal models of chemotherapy-induced cognitive decline in preclinical drug development

“…Altered brain connectivity due to chemotherapy can disrupt the hippocampus's structure and function, which could directly contribute to impairment in different cognitive domains, particularly long-term and short-term memory. Changes in the prefrontal cortex were also found to be associated with CICI manifesting alterations in memory, attention, and executive functions Peukert et al 2020).…”

Altered Regional Brain Glucose Metabolism in Diffuse Large B-Cell Lymphoma Patients Treated With Cyclophosphamide, Epirubicin, Vincristine, and Prednisone: An Fluorodeoxyglucose Positron Emission Tomography Study of 205 Cases

“…Both animal and preclinical clinical studies have revealed that the hippocampus and the frontal lobes are particularly vulnerable to the adverse effects of chemotherapy ( Winocur et al, 2018 ; Peukert et al, 2020 ). As early as 2004, Rzeski et al (2004) found that cytotoxic drugs could extensively damage the hippocampal dentate gyrus of 7-day-old rats.…”